Abstract
The selective cyclooxygenase-2 inhibitor, celecoxib, can be prescribed to type 2 diabetic patients receiving oral hypoglycemic agents. This study was conducted to assess whether celecoxib affect the hypoglycemic activity of oral hypoglycemic agents in streptozotocin-induced diabetic rats by measuring blood glucose level followed by determination of glucose uptake of isolated rat epididymal fat pads. Also, the effect of anti-diabetic agents on the anti-inflammatory activity of celecoxib was also assessed using carrageenan-induced hind paw edema model in diabetic rats.This study revealed that the effect of celecoxib on the hypoglycemic activity of glibenclamide was additive and can be explained by stimulation of tissue glucose uptake by celecoxib. On the other hand, the effect of celecoxib on the hypoglycemic activity of glimepiride was not simple additive but synergistic. This synergistic effect can be explained not only by stimulation of tissue glucose uptake by celecoxib but also via a pharmacokinetic interaction by increasing the serum glimepiride concentration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
